Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a member of a class of molecules called halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of li… Read more
Provectus Biopharmaceuticals Inc (PVCT) - Total Liabilities
Latest total liabilities as of September 2025: $6.59 Million USD
Based on the latest financial reports, Provectus Biopharmaceuticals Inc (PVCT) has total liabilities worth $6.59 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Provectus Biopharmaceuticals Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how Provectus Biopharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Provectus Biopharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Provectus Biopharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Arihant Capital Markets Limited
NSE:ARIHANTCAP
|
India | ₹5.51 Billion |
|
King Stone Energy Group Limited
PINK:YNSKF
|
USA | $197.56 Million |
|
Alkindo Naratama Tbk
JK:ALDO
|
Indonesia | Rp990.37 Billion |
|
Robo.ai Inc.
NASDAQ:AIIO
|
USA | $104.16 Million |
|
Cowealth Medical Holding Co Ltd
TWO:4745
|
Taiwan | NT$1.94 Billion |
|
Vivid Seats Inc
NASDAQ:SEAT
|
USA | $771.58 Million |
|
Mercor S.A.
WAR:MCR
|
Poland | zł106.46 Million |
|
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
|
Germany | €633.60 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Provectus Biopharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 15.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Provectus Biopharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Provectus Biopharmaceuticals Inc (2001–2024)
The table below shows the annual total liabilities of Provectus Biopharmaceuticals Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.98 Million | -22.86% |
| 2023-12-31 | $9.04 Million | +9.39% |
| 2022-12-31 | $8.27 Million | +7.34% |
| 2021-12-31 | $7.70 Million | -74.99% |
| 2020-12-31 | $30.80 Million | +20.54% |
| 2019-12-31 | $25.55 Million | +31.66% |
| 2018-12-31 | $19.41 Million | +44.22% |
| 2017-12-31 | $13.46 Million | +528.21% |
| 2016-12-31 | $2.14 Million | -48.05% |
| 2015-12-31 | $4.12 Million | +314.66% |
| 2014-12-31 | $994.28K | -92.57% |
| 2013-12-31 | $13.38 Million | +638.79% |
| 2012-12-31 | $1.81 Million | -45.62% |
| 2011-12-31 | $3.33 Million | -10.07% |
| 2010-12-31 | $3.70 Million | +347.76% |
| 2009-12-31 | $827.00K | +79.00% |
| 2008-12-31 | $462.00K | -47.50% |
| 2007-12-31 | $880.00K | +9.59% |
| 2006-12-31 | $803.00K | -72.61% |
| 2005-12-31 | $2.93 Million | +44.15% |
| 2004-12-31 | $2.03 Million | +13.89% |
| 2003-12-31 | $1.79 Million | +53.17% |
| 2002-12-31 | $1.17 Million | +29050.00% |
| 2001-12-31 | $4.00K | -- |